Cidofovir Anhydrous: Side Effects, Uses & Monitoring
VISTIDE is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).
- Data source
- FDA labeling via NIH DailyMed (label 90639fc6…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
| Adverse reaction (as reported in labeling) | Reported frequency* |
|---|---|
| Proteinuria (≥ 30 mg/dl) | 101% |
| Nausea +/- vomiting | 79% |
| Proteinuria (≥ 100 mg/dl) | 68% |
| Neutropenia (< 750 cells/mm3 ) | 50% |
| Asthenia | 50% |
| Headache | 34% |
| Rash | 34% |
| Neutropenia (≤ 500 cells/mm3 ) | 33% |
| Alopecia | 31% |
| Diarrhea | 30% |
| Pain | 29% |
| Creatinine elevation (> 1.5 mg/dl) | 28% |
| Anemia | 28% |
| Anorexia | 26% |
| Chills | 25% |
| Increased cough | 22% |
| Decreased serum bicarbonate (≤ 16 meq/l) | 21% |
| Oral moniliasis | 21% |
| Fever | 19% |
| Infection | 16% |
*Highest percentage reported for the active moiety across placebo-controlled trial tables in current FDA labeling. Values reflect trial reporting, not your individual risk.
Labeled uses (from FDA prescribing information)
VISTIDE is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). THE SAFETY AND EFFICACY OF VISTIDE HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (SUCH AS PNEUMONITIS OR GASTROENTERITIS), CONGENITAL OR NEONATAL CMV DISEASE, OR CMV DISEASE IN NON-HIV-INFECTED INDIVIDUALS.
Conditions associated with Cidofovir Anhydrous in labeling
Frequently Asked Questions
What is Cidofovir Anhydrous used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Cidofovir Anhydrous?
The table above shows adverse reactions and the highest frequencies reported in placebo-controlled trials summarized in current FDA labeling for Cidofovir Anhydrous. Individual risk varies.
Does Cidofovir Anhydrous require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Cidofovir Anhydrous.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.